Acute chlamydia pneumoniae reinfection accelerates the development of insulin resistance and diabetes in obese C57BL/6 mice

Journal of Infectious Diseases

Volumn 200, Issue 2, 2009, Pages 279-287

  Wang, Chengming ^a   Gao, Dongya ^a   Kaltenboeck, Bernhard ^a  

^a AUBURN UNIVERSITY   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

AZITHROMYCIN; TUMOR NECROSIS FACTOR ALPHA; TUMOR NECROSIS FACTOR ALPHA ANTIBODY;

ADIPOSE TISSUE; ANIMAL EXPERIMENT; ANIMAL MODEL; ARTICLE; BACTERIAL COLONIZATION; CHLAMYDIASIS; CHLAMYDOPHILA PNEUMONIAE; CONTROLLED STUDY; CYTOKINE RELEASE; DIABETES MELLITUS; DISEASE EXACERBATION; FAT INTAKE; INSULIN RESISTANCE; MALE; MOUSE; NONHUMAN; OBESITY; PATHOPHYSIOLOGY; PRIORITY JOURNAL;

ACUTE DISEASE; ANIMALS; AZITHROMYCIN; CHLAMYDOPHILA INFECTIONS; CHLAMYDOPHILA PNEUMONIAE; DIABETES MELLITUS, TYPE 2; FATTY ACIDS, NONESTERIFIED; INSULIN RESISTANCE; MALE; MICE; MICE, INBRED A; MICE, INBRED C57BL; MICE, OBESE; OBESITY; PNEUMONIA, BACTERIAL; RECURRENCE; TUMOR NECROSIS FACTOR-ALPHA;

EID: 67650682783     PISSN: 00221899     EISSN: None     Source Type: Journal    
DOI: 10.1086/599796     Document Type: Article

References (48)

1. Hotamisligil GS, Shargill NS, Spiegelman BM. Adipose expression of tumor necrosis factor-a: direct role in obesity-linked insulin resistance. Science 1993;259:87-91.
2. Xu H, Barnes GT, Yang Q, et al. Chronic inflammation in fat plays a crucial role in the development of obesity-related insulin resistance. J Clin Invest 2003;112:1821-30.
3. Rosen ED, Spiegelman BM. Adipocytes as regulators of energy balance and glucose homeostasis. Nature 2006;444:847-53.
4. Weisberg SP, McCann D, Desai M, Rosenbaum M, Leibel RL, Ferrante AW Jr. Obesity is associated with macrophage accumulation in adipose tissue. J Clin Invest 2003; 112:1796-808.
5. Huang J, DeGraves FJ, Lenz SD, et al. The quantity of nitric oxide released by macrophages regulates Chlamydia- induced disease. Proc Natl Acad Sci U S A 2002;99:3914-9.
6. Nieto FJ. Infections and atherosclerosis: new clues from an old hypothesis? Am J Epidemiol 1998; 148:937-48.
7. Campbell LA, Kuo CC. Chlamydia pneumoniae-an infectious risk factor for atherosclerosis? Nat Rev Microbiol 2004; 2:23-32.
8. Kuo C, Campbell LA. Detection of Chlamydia pneumoniae in arterial tissues. J Infect Dis 2000; 181(Suppl 3):S432-6.
9. Saikku P, Leinonen M, Mattila K, et al. Serological evidence of an association of a novel Chlamydia, TWAR, with chronic coronary heart disease and acute myocardial infarction. Lancet 1988;2(8618):983-6.
10. Aydemir S, Bayraktaroglu T, Sert M, et al. The effect of Helicobacter pylori on insulin resistance. Dig Dis Sci 2005; 50:2090-3.
11. Mealey BL, Rose LF. Diabetes mellitus and inflammatory periodontal diseases. Curr Opin Endocrinol Diabetes Obes 2008; 15:135-41.
12. Narita R, Abe S, Kihara Y, Akiyama T, Tabaru A, Otsuki M. Insulin resistance and insulin secretion in chronic hepatitis C virus infection. J Hepatol 2004;41:132-8.
13. Shintani Y, Fujie H, Miyoshi H, et al. Hepatitis C virus infection and diabetes: direct involvement of the virus in the development of insulin resistance. Gastroenterology 2004; 126:840-8.
14. Aboud M, Elgalib A, Kulasegaram R, Peters B. Insulin resistance and HIV infection: a review. Int J Clin Pract 2007;61:463-72.
15. Madjid M, Awan I, Ali M, Frazier L, Casscells W Influenza and atherosclerosis: vaccination for cardiovascular disease prevention. Expert Opin Biol Ther 2005;5:91-6.
16. Espinola-Klein C, Rupprecht HJ, Blankenberg S, et al. Impact of infectious burden on progression of carotid atherosclerosis. Stroke 2002; 33:2581-6.
17. Kuo CC, Jackson LA, Campbell LA, Grayston JT. Chlamydia pneumoniae (TWAR). Clin Microbiol Rev 1995;8:451-61.
18. Boman J, Söderberg S, Forsberg J, et al. High prevalence of Chlamydia pneumoniae DNA in peripheral blood mononuclear cells in patients with cardiovascular disease and in middle-aged blood donors. J Infect Dis 1998; 178:274-7.
19. Smieja M, Mahony J, Petrich A, Boman J, Chemesky M. Association of circulating Chlamydia pneumoniae DNA with cardiovascular disease: a systematic review. BMC Infect Dis 2002; 2:21.
20. Nabipour I, Vahdat K, Jafari SM, Pazoki R, Sanjdideh Z. The association of metabolic syndrome and Chlamydia pneumoniae, Helicobacter pylori, cytomegalovirus, and herpes simplex virus type 1: the Persian Gulf Healthy Heart Study. Cardiovasc Diabetol 2006; 5:25.
21. Ekesbo R, Nilsson PM, Lindholm LH, Persson K, Wadström T. Combined seropositivity for H. pylori and C. pneumoniae is associated with age, obesity and social factors. J Cardiovasc Risk 2000;7:191-5.
22. Campbell LA, Moazed TC, Kuo CC, Grayston JT. Preclinical models for Chlamydia pneumoniae and cardiovascular disease: hypercholesterolemic mice. Clin Microbiol Infect 1998;4(Suppl 4):S23-S32.
23. Dart AM, Martin JL, Kay S. Association between past infection with Chlamydia pneumoniae and body mass index, low-density lipoprotein particle size and fasting insulin. Int J Obes Relat Metab Disord 2002;26: 464-8.
24. Fernández-Real JM, López-Bermejo A, Vendrell J, Ferri MJ, Recasens M, Ricart W. Burden of infection and insulin resistance in healthy middle-aged men. Diabetes Care 2006;29:1058-64.
25. Gupta S, Leatham EW, Carrington D, Mendall MA, Kaski JC, Camm AJ. Elevated Chlamydia pneumoniae antibodies, cardiovascular events, and azithromycin in male survivors of myocardial infarction. Circulation 1997;96:404-7.
26. Falck G, Gnarpe J, Hansson LO, Svärdsudd K, Gnarpe H. Comparison of individuals with and without specific IgA antibodies to Chlamydia pneumoniae: respiratory morbidity and the metabolic syndrome. Chest 2002;122:1510-2.
27. Cannon CP, Braunwald E, McCabe CH, et al. Antibiotic treatment of Chlamydia pneumoniae after acute coronary syndrome. N Engl J Med 2005;352:1646-54.
28. Grayston JT, Kronmal RA, Jackson LA, et al. Azithromycin for the secondary prevention of coronary events. N Engl J Med 2005; 352: 1637-45.
29. O'Connor CM, Dunne MW, Pfeffer MA, et al. Azithromycin for the secondary prevention of coronary heart disease events: the WIZARD study: a randomized controlled trial. JAMA 2003;290:1459-66.
30. Muhlestein JB. Secondary prevention of coronary artery disease with antimicrobials: current status and future directions. Am J Cardiovasc Drugs 2002;2:107-18.
31. Duncan MH, Singh BM, Wise PH, Carter G, Alaghband-Zadeh J. A simple measure of insulin resistance. Lancet 1995;346:120-1.
32. Yang Q, Graham TE, Mody N, et al. Serum retinol binding protein 4 contributes to insulin resistance in obesity and type 2 diabetes. Nature 2005;436:356-62.
33. Surwit RS, Kuhn CM, Cochrane C, McCubbin JA, Feinglos MN. Dietinduced type II diabetes in C57BL/6J mice. Diabetes 1988;37:1163-7.
34. Wang C, van Ginkel FW, Kim T, et al. Temporal delay of peak T cell immunity determines Chlamydia pneumoniae pulmonary disease in mice. Infect Immun 2008;76:4913-23.
35. Stevenson MM, Kongshavn PA, Skamene E. Genetic linkage of resistance to Listeria monocytogenes with macrophage inflammatory responses. J Immunol 1981; 127:402-7.
36. Sartipy P, Loskutoff DJ. Monocyte chemoattractant protein 1 in obesity and insulin resistance. Proc Natl Acad Sci U S A 2003; 100:7265-70.
37. Campbell LA, Nosaka T, Rosenfeld ME, Yaraei K, Kuo CC. Tumor necrosis factor alpha plays a role in the acceleration of atherosclerosis by Chlamydia pneumoniae in mice. Infect Immun 2005;73:3164-5.
38. Gieffers J, Füllgraf H, Jahn J, et al. Chlamydia pneumoniae infection in circulating human monocytes is refractory to antibiotic treatment. Circulation 2001; 103:351-6.
39. Feinstein R, Kanety H, Papa MZ, Lunenfeld B, Karasik A. Tumor necrosis factor-alpha suppresses insulin-induced tyrosine phosphorylation of insulin receptor and its substrates. J Biol Chem 1993; 268: 26055-8.
40. Laurencikiene J, van Harmelen V, Arvidsson Nordström E, et al. NFKB is important for TNF-a- induced lipolysis in human adipocytes. J Lipid Res 2007;48:1069-77.
41. Souza SC, Palmer HJ, Kang YH, et al. TNF-alpha induction of lipolysis is mediated through activation of the extracellular signal related kinase pathway in 3T3-L1 adipocytes. J Cell Biochem 2003;89:1077-86.
42. Gurfinkel E, Bozovich G, Beck E, Testa E, Livellara B, Mautner B. Treatment with the antibiotic roxithromycin in patients with acute non- Q-wave coronary syndromes. The final report of the ROXIS Study. Eur Heart J 1999;20:121-7.
43. Sander D, Winbeck K, Klingelhöfer J, Etgen T, Conrad B. Reduced progression of early carotid atherosclerosis after antibiotic treatment and Chlamydia pneumoniae seropositivity. Circulation 2002; 106:2428-33.
44. Neumann F, Kastrati A, Miethke T, et al. Treatment of Chlamydia pneumoniae infection with roxithromycin and effect on neointima proliferation after coronary stent placement (ISAR-3): a randomised, double-blind, placebo-controlled trial. Lancet 2001;357:2085-9.
45. Sander D, Winbeck K, Klingelhöfer J, Etgen T, Conrad B. Reduced progression of early carotid atherosclerosis after antibiotic treatment and Chlamydia pneumoniae seropositivity. Circulation 2002; 106:2428-33.
46. Jespersen CM, Als-Nielsen B, Damgaard M, et al. Randomised placebo controlled multicentre trial to assess short term clarithromycin for patients with stable coronary heart disease: CLARICOR trial. BMJ 2006;332:22-7.
47. Hahn DL. Chlamydia pneumoniae, asthma, and COPD: what is the evidence? Ann Allergy Asthma Immunol 1999;83:271-88, 291-2.
48. Karnak D, Beder S. Treatment of Chlamydia pneumoniae infection and chronic obstructive pulmonary disease. Expert Opin Pharmacother 2002;3:1461-70.